Homocysteine levels in patients with deep vein thrombosis lacking thrombophilic defects

• References

• 1 Cattaneo M. Hyperhomocysteinemia and venous thromboembolism. Semin Thromb Hemost 2006; 32: 716-723.
• 2 Gatt A, Makris M. Hyperhomocysteinemia and venous thrombosis. Semin Hematol 2007; 44: 70-76.
• 3 den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a metaanalysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-299.
• 4 Frederiksen J, Juul K, Grande P. et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and casecontrol studies from the Copenhagen City Heart Study. Blood 2004; 104: 3046-3051.
• 5 Marcucci R, Gori AM, Abbate R. Hyperhomocysteinemia: cause or effect of disease?. Blood 2005; 105: 3382-3383.
• 6 Schneede J, Refsum H, Ueland PM. Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost 2000; 26: 263-279.
• 7 Brattström L, Tengborn L, Lagerstedt C. et al. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-57.
• 8 Den Heijer M, Blom HJ, Gerrits WBJ. et al. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis?. Lancet 1995; 345: 882-885.
• 9 Ridker PM, Hennekens CH, Selhub J. et al. Interrelation of hyperhomocysteinemia, factor V Leiden and risk of future venous thromboembolism. Circulation 1997; 95: 1777-1782.
• 10 den Heijer M, Koster T, Blom HJ. et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.
• 11 Lijfering WM, Coppens M, van de Poel MHW. et al. The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007; 98: 457-463.
• 12 Martínez-Frias ML, Bermejo E, Rodríguez-Pinilla E. et al. Frequency of the mutation 677C-T of methylenetetrahydrofolate reductase gene on a sample of 652 Spanish liveborn infants. Med Clin (Barc) 2004; 122: 361-364.
• 13 Corella D, Cortina P, Guillen M. et al. Dietary habits and geographical variation in stomach cancer mortality in Spain. Eur J Cancer Prev 1996; 5: 249-257.
• 14 Vargas M, Soto I, Pinto CR. et al. Mild hyperhomocysteinemia and MTHFR C677-T do not increase the risk for venous thrombosis in a Spanish population. Blood Coagul Fibrin 1998; 9: 555-556.
• 15 González Y, Souto JC, Mateo J. et al. Moderate hyperhomocysteinemia is a highly prevalent defect in Spanish patients with venous thromboembolic disease. Haematologica 1998; 83: 1126-1127.
• 16 Dudman NP. An alternative view of homocysteine. Lancet 1999; 354: 2072-2074.
• 17 Ricart JM, Vayá A, Todolí J. et al. Thrombophilic risk factors and homocysteine levels in Behçet’s disease in eastern Spain and their association with thrombotic events. Thromb Haemost 2006; 95: 618-624.
• 18 Keijzer MB, den Heijer M, Blom HJ. et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002; 88: 723-728.
• 19 Hankey GJ, Elkelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-413.
• 20 Ray J, Gmm Kearon C, Yi Q, Sheridan P. et al. Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomised trial. Ann Intern Med 2007; 146: 761-767.
• 21 den Heijer M, Willems HP, Blom HJ. et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007; 109: 139-144.